CASI Hosts Nobel Laureate James P. Allison
September 10, 2019
CASI hosts a key opinion leader (KOL) symposium addressing innovations in cancer immunotherapy. A replay of the webcast can be found at https://edge.media-server.com/mmc/p/py99t7is.
Evomela Commercially Available In China
August 12, 2019
EVOMELA® received market approval by the China National Medical Products Administration (NMPA) for use as high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplant in patients with multiple myeloma, and as a palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. It is the only approved and commercially available melphalan product in China.
U.S. FDA-Approved Products In-Licensed for the Greater China Region
Pre-Clinical Drug Candidates